Department of Molecular, Cellular, and Biomedical Sciences, Rudman Hall, University of New Hampshire, NH 03824, Durham, USA.
Sci Rep. 2016 Oct 10;6:34916. doi: 10.1038/srep34916.
Huntington's disease (HD) results from expansions of polyglutamine stretches (polyQ) in the huntingtin protein (Htt) that promote protein aggregation, neurodegeneration, and death. Since the diversity and sizes of the soluble Htt-polyQ aggregates that have been linked to cytotoxicity are unknown, we investigated soluble Htt-polyQ aggregates using analytical ultracentrifugation. Soon after induction in a yeast HD model system, non-toxic Htt-25Q and cytotoxic Htt-103Q both formed soluble aggregates 29S to 200S in size. Because current models indicate that Htt-25Q does not form soluble aggregates, reevaluation of previous studies may be necessary. Only Htt-103Q aggregation behavior changed, however, with time. At 6 hr mid-sized aggregates (33S to 84S) and large aggregates (greater than 100S) became present while at 24 hr primarily only mid-sized aggregates (20S to 80S) existed. Multiple factors that decreased cytotoxicity of Htt-103Q (changing the length of or sequences adjacent to the polyQ, altering ploidy or chaperone dosage, or deleting anti-aging factors) altered the Htt-103Q aggregation pattern in which the suite of mid-sized aggregates at 6 hr were most correlative with cytotoxicity. Hence, the amelioration of HD and other neurodegenerative diseases may require increased attention to and discrimination of the dynamic alterations in soluble aggregation processes.
亨廷顿病(HD)是由亨廷顿蛋白(Htt)中的多聚谷氨酰胺延伸(polyQ)扩展引起的,该延伸促进了蛋白质聚集、神经退行性变和死亡。由于与细胞毒性相关的可溶性 Htt-polyQ 聚集物的多样性和大小未知,我们使用分析超速离心法研究了可溶性 Htt-polyQ 聚集物。在酵母 HD 模型系统中诱导后不久,非毒性 Htt-25Q 和细胞毒性 Htt-103Q 都形成了大小为 29S 至 200S 的可溶性聚集物。由于目前的模型表明 Htt-25Q 不会形成可溶性聚集物,因此可能需要重新评估以前的研究。然而,只有 Htt-103Q 的聚集行为随时间而变化。在 6 小时时,出现了中等大小的聚集物(33S 至 84S)和大聚集物(大于 100S),而在 24 小时时,主要存在中等大小的聚集物(20S 至 80S)。多种降低 Htt-103Q 细胞毒性的因素(改变 polyQ 的长度或相邻序列、改变ploidy 或 chaperone 剂量、或删除抗衰老因子)改变了 Htt-103Q 的聚集模式,其中 6 小时时的中等大小聚集物与细胞毒性相关性最强。因此,亨廷顿病和其他神经退行性疾病的改善可能需要更加关注和区分可溶性聚集过程的动态变化。